Revenue Insights: Teva Pharmaceutical Industries Limited and Dynavax Technologies Corporation Performance Compared

Pharma Revenue Trends: Teva vs. Dynavax Over a Decade

__timestampDynavax Technologies CorporationTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20141103200020272000000
Thursday, January 1, 2015405000019652000000
Friday, January 1, 20161104300021903000000
Sunday, January 1, 201732700022385000000
Monday, January 1, 2018819800018854000000
Tuesday, January 1, 20193521900016887000000
Wednesday, January 1, 20204655100016658000000
Friday, January 1, 202143944200015878000000
Saturday, January 1, 202272268300014925000000
Sunday, January 1, 202323228400015846000000
Monday, January 1, 202416544000000
Loading chart...

Infusing magic into the data realm

Revenue Trends in the Pharmaceutical Industry: A Comparative Analysis

In the ever-evolving pharmaceutical landscape, understanding revenue trends is crucial for investors and industry stakeholders. This analysis compares the annual revenue performance of Teva Pharmaceutical Industries Limited and Dynavax Technologies Corporation from 2014 to 2023.

Key Insights

Teva, a global leader, consistently reported revenues exceeding $15 billion annually, peaking in 2017. However, a gradual decline of approximately 29% was observed by 2022, reflecting industry challenges and market dynamics. In contrast, Dynavax, a smaller biotech firm, showcased remarkable growth. From a modest $11 million in 2014, its revenue surged by over 6,400% to $723 million in 2022, driven by strategic innovations and market expansion.

Conclusion

This decade-long analysis highlights the contrasting trajectories of a pharmaceutical giant and an emerging biotech player, offering valuable insights into market adaptability and growth potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025